LPTX
- Leap Therapeutics, Inc.
()
Overview
Company Summary
Leap Therapeutics, Inc. (LPTX) is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's primary objective is to develop innovative therapies that address significant unmet medical needs in the oncology field.
LPTX utilizes a unique approach to drug development, leveraging its expertise in antibody-based therapeutics. Their research and development efforts are centered around developing antibodies that target specific proteins or pathways involved in the growth and progression of various types of cancer.
The company's lead product candidate, DKN-01, is a monoclonal antibody that targets the Dickkopf-1 (DKK1) protein. DKK1 is known to play a role in tumor growth and is found to be upregulated in several cancer types, including esophageal, gastroesophageal junction, and cholangiocarcinoma cancers. LPTX is currently evaluating DKN-01 in multiple clinical trials, including a phase III trial for advanced gastroesophageal junction cancer.
In addition to DKN-01, Leap Therapeutics is also advancing several other preclinical and clinical-stage programs. These include T-cell bispecific antibodies and targeted small molecules, which target specific signaling pathways critical to cancer cell survival and proliferation.
The ultimate goal of Leap Therapeutics is to develop therapies that improve patient outcomes and survival rates by selectively targeting cancer cells while minimizing side effects. Through their innovative approach and commitment to developing effective oncology treatments, LPTX aims to make a significant impact in the field of cancer therapeutics.